Tag Archives: merck

Scientists May Have Finally Found a Way to Stop Ebola

Mother Jones

<!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.0 Transitional//EN” “http://www.w3.org/TR/REC-html40/loose.dtd”>

Scientists have developed a vaccine that could successfully prevent the spread of Ebola, according to a study published Thursday in The Lancet. The study was conducted in response to the West African Ebola crisis—the largest and deadliest recorded Ebola outbreak to date—and is the first to report a promising solution for the deadly virus.

Since December 2013, Ebola—a highly infectious virus that causes severe hemorrhagic fevers and has a 50 percent fatality rate—has killed over 11,300 people in West Africa. Considered a global health crisis, the outbreak took nearly two years to control and was complicated by a lack of international funding and widespread fear and mistrust of doctors among African locals. Though the virus was discovered in 1976, early attempts to develop vaccines stalled in the absence of financial incentives for pharmaceutical companies. Until 2014, Ebola outbreaks were rare and controlled relatively quickly.

“While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenseless,” said Dr. Marie-Paule Kieny, the World Health Organization’s assistant director-general for health systems and innovation, and a lead author of the study, in a press release accompanying the study.

Amid the Ebola crisis, researchers from the WHO and more than a dozen other international partners, tested the new vaccine on 5,937 at-risk individuals in Guinea and found it was 100 percent effective when administered soon after exposure. None of the roughly 3,900 people vaccinated within three weeks of Ebola exposure ended up catching the virus 10 or more days after the vaccination. (Researchers discounted any individuals who got Ebola within 10 days—the typical incubation period for the virus—under the assumption that they had already contracted it prior to vaccination.) The vaccine appears to be less effective the longer the researches waited after an exposure: Of the roughly 2,000 people vaccinated more than three weeks after an exposure, 16 got Ebola.

To find people at risk of getting Ebola, researchers used a unique method, “ring vaccination,” inspired by the strategy used to eradicate smallpox in the 1970s. Each time a new Ebola case was confirmed, researchers traced all the people the patient had come in direct contact with, as well as the people who had come in contact with those people within the previous three weeks. The clusters, or “rings,” were then randomly assigned to either immediate or delayed vaccinations. After noticing positive results in the first few months, the researchers stopped the delayed vaccinations altogether. Eventually, the researchers began vaccinating children, which was also 100 percent effective.

The “ring vaccination” technique additionally had a positive impact on public health: Communities of those who were vaccinated were also less likely to get sick. That proved crucial not only in studying the vaccine, but also in quashing the outbreak itself.

The team still needs to do more research on the safety of the vaccine in children and other vulnerable populations, such as people with HIV. Other questions also remain about how long the protective effects of a single vaccination can last and whether it can be modified to reduce side effects without compromising efficacy.

In the meantime, the Global Alliance for Vaccines and Immunization, a global health partnership that includes the WHO, gave $5 million to pharmaceutical giant Merck in January to procure the vaccine after its approval. Merck also committed to making 300,000 doses of the vaccine available, should an emergency arise in the interim.

“Ebola left a devastating legacy in our country,” Dr KeÏta Sakoba, coordinator of the Ebola response in Guinea, said in the press release. “We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured.”

Jump to original:

Scientists May Have Finally Found a Way to Stop Ebola

Posted in FF, GE, LAI, LG, ONA, Radius, Uncategorized, Venta | Tagged , , , , , , , , , , | Comments Off on Scientists May Have Finally Found a Way to Stop Ebola

This Company Gave Away a Drug That Just Won the Nobel Prize and Helped Millions

Mother Jones

<!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.0 Transitional//EN” “http://www.w3.org/TR/REC-html40/loose.dtd”>

Earlier today, the Nobel committee awarded its renowned prize for medicine to the discoverers of two anti-parasitic drugs — one that fights malaria and one that treats two lesser-known devastating diseases.

The latter, ivermectin, treats lymphatic filariasis and river blindness, which are parasites that have plagued humans for centuries and currently threaten 1.35 billion people around the world. Developing drugs to treat infectious diseases and making them available to the often-impoverished people who need them is extremely difficult. But because of a breakthrough and an unprecedented move by one of the largest pharmaceutical companies in the world, these diseases might soon be eradicated.

Satoshi Omura Kyodo/AP

Lymphatic filariasis, which can develop into a condition known as elaphantiasis, is a mosquito-transmitted worm that lodges in the lymphatic system, impairing it along with the victim’s immune system and kidneys. In the worst cases, the worm causes extreme swelling and disfigurement of tissue, limbs, and genital parts. According to the World Health Organization (WHO) 40 million people, mostly in African and South Asian countries are incapacitated by the disease, and shunned because of their disfigurement.

Onchocerciasis, or river blindness, is a worm spread through the bite of a blackfly, which breeds in rivers. The parasite produces larvae that move through human tissue, causing sever itching and skin rashes, as well as eye lesions, which can lead to severe visual impairment. An estimated 270,000 people are currently blinded by the disease. The vast majority of people at-risk live in Africa, where it has taken a huge economic toll on rural communities, which have had to move away from rivers to less productive land in order to avoid the disease.

William Campbell Mary Schwalm/AP

In the late 1970s, Satoshi Omura, a scientist at the Kitasato Institute in Tokyo found a component of a soil-dwelling bacteria (that’s right, he literally found it in the dirt) called Streptomyces that was very effective at killing parasites. He then sent cultures of this bacteria to William Campbell in New Jersey who worked for Merck & Co., the fourth largest pharmaceutical company in the world. There, Campbell successfully developed a drug called ivermectin from a compound in the bacteria culture. The discovery was a huge pharmaceutical breakthrough and the drug was determined to be extremely safe for humans and easily distributed.

But, as with many infectious disease drugs, the vast majority of people who needed it lived in the developing world and could not afford it.

What happened next was unprecedented.

In 1987, Merck announced it would partner with the WHO and donate Mectizan, the drug’s brand name, to any country who requested it for as long as they needed it. Before this, no large pharmaceutical company had ever given away a drug they developed to eradicate a disease. At a news conference after Merck’s announcement, the late Massachusetts senator Ted Kennedy said, “Merck’s gift to the World Health Organization is more than a medical breakthrough–it is truly a triumph of the human spirit.”

Since 1987, the Mectizan Donation Program has given out more than a billion treatments for onchoceriasis and lymphatic filariasis to people in 33 countries (in the late ’90s GlaxoSmithKline contributed another drug for lymphatic filariasis to the program). As a result, the transmission of onchoceriasis has been stopped in many countries. Last year Ecuador became the second affected country, after Colombia, to entirely eradicate the disease. Lymphatic filariasis cases have dramatically decreased, as well. The WHO forecasts that both diseases could be eliminated by 2020.

Omura and Campbell were awarded the Nobel Prize in medicine for their work.

The Nobel committee said ivermectin’s importance was “immeasurable” for the health of many in the world’s poorest regions.

“Treatment is so successful that these diseases are on the verge of eradication, which would be a major feat in the medical history of humankind,” the committee said.

Source:  

This Company Gave Away a Drug That Just Won the Nobel Prize and Helped Millions

Posted in alo, Anchor, FF, Free Press, G & F, GE, LAI, LG, ONA, Radius, Uncategorized, Venta | Tagged , , , , , , , | Comments Off on This Company Gave Away a Drug That Just Won the Nobel Prize and Helped Millions